Press Release
Title:
Pure Hypericin Process
Discription:
Analytica recently has developed a novel technology for preparing an extract of St. John's Wort that is highly enriched into two biantraquinones: hypericin and pseudohypericin. St. John's Wort is best known for the relieve of symptoms of mild depression. While there is no rigorously established relationship between the hypericins and relieve of symptoms of depression, many scientists suggest that hypericins play an important role in the treatment. Commercial extracts of St. John's Wort are often standardized to 0.3 % of hypericins, which means that they also contain many other components. The extract made by Planta Analytica contains between 80 and 95% of the hypericins with both proto pigments: protopseudohypericin and protohypericin being the main contaminants and can be used for the pharmacological studies.
Title:
PhytoMedical Announces Agreement with Celliance BioServices, Inc. to Conduct Animal Studies of BDC-03.
Discription:
Publication: Business Wire Publication Date: 22-FEB-05 Format: Online - approximately 1418 words Delivery: Immediate Online Access Author: Company: Serologicals Corp. Article Excerpt VANCOUVER, British Columbia -- PhytoMedical Technologies, Inc. (OTCBB:PYTO), an early stage research based biopharmaceutical company specializing in the discovery, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds, today announced that the Company has signed an Agreement with Celliance BioServices, Inc. of Celliance(TM) Corporation -- a Serologicals Company -- to initiate further animal studies of BDC-03, a plant derived compound which has been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals. Under the terms of the Agreement, Celliance BioServices will conduct PhytoMedical's ongoing, early stage in vivo studies at its laboratories in Morgan Hill, California, a 30,000 square foot research facility known for its expertise in front-end, biopharmaceutical product development pipeline R&D. "I'm very pleased that we've been able to enlist the expert scientific support of a well-respected leader in biopharmaceutical research and development services for these particular animal studies of BDC-03," commented President of PhytoMedical Technologies, Mr. Indy S. Panchi. "These animal studies are especially important to us since they are designed to generate outcomes we believe will allow us to fully leverage PhytoMedical's recently announced extraction-fractionation-isolation research initiative with PlantaAnalytica, LLC, a Connecticut-based drug discovery contract research firm with special expertise in organic chemistry and in isolating active components from microbial and plant extracts such... NOTE: All illustrations and photos have been removed from this article.
Title:
Alkaloids from Eschscholzia californica
Discription:
A 70% ethanol extract of California poppy (Eschscholzia californica) was able to bind to 5-HT1A and 5-HT7 receptors at 100 g/mL. The subsequent isolation procedure yielded the known alkaloids californidine (1), escholtzine (2), N-methyllaurotetanine (3), caryachine (4), and O-methylcaryachine (5), along with a new pavine alkaloid, 6S,12S-neocaryachine-7-O-methyl ether N-metho salt (7). The structure of 7 was determined by spectroscopic data interpretation, while the absolute stereochemistry was determined by means of circular dichroism. From the results obtained from the radioligand-binding assay of the pure compounds, including the commercially available protopine (6), it was evident that the activity on the 5-HT1A receptor was at least partly due to the presence of the aporphine alkaloid 3, which showed the highest inhibition of [3H]8-hydroxy-2-(di-N-propylamino)tetralin ([3H]8-OH-DPAT) binding with an EC50 value of 155 nM and a Ki of 85 nM. --------------------------------------------------------------------------------
© 200
7
Planta Analytica. All rights reserved.
